BioSpace News Archive

SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a technology company providing life sciences instrumentation and research services, today announced a new study demonstrating early cancer detection using SeqLL’s single-molecule technology was published in the peer-reviewed journal Nature Biotechnology.

Mereo BioPharma Group plc reported updated clinical data and promising biomarker data from ACTIVATE, a Phase 1b/ 2 study of anti-TIGIT antibody, etigilimab, in combination with nivolumab, in select recurrent advanced / metastatic solid tumors.

Microbot Medical Inc. announces the commencement of its GLP Pre-Clinical Trial for the LIBERTY Robotic System at a world-class MedTech research laboratory.

MediWound Ltd. announced its successful and meaningful presence at the recently concluded 19th European Burns Association Congress held in Turin, Italy on September 7-10, 2022.

Akari Therapeutics, Plc announced it has entered into definitive agreements with healthcare-focused institutional investors alongside participation from certain existing investors, including the Akari Executive Chairman of the Board of Directors, Dr. Ray Prudo, for the purchase and sale of 15,000,000 Akari American Depository Shares at a purchase price of $0.85 per ADS.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the U.S. Food and Drug Administration (FDA) has granted a small business waiver of the Prescription Drug User Fee Act (PDUFA) fee of $3.1 million for the 505(b)(2) New Drug Application (NDA) for Nyxol (phentolamine ophthalmic solution), the Company’s late stage product candidate.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”) today announced updated data from an investigator-sponsored Phase 1/2a trial of oral rigosertib plus the anti-PD-1 immune checkpoint inhibitor (ICI) nivolumab in advanced KRAS-mutated (KRAS+) non-small cell lung cancer (NSCLC).

Ascendis Pharma A/S (Nasdaq: ASND) today announced new Week 110 data from the Phase 2 PaTH Forward Trial showing that long-term therapy with TransCon PTH, an investigational prodrug designed to provide sustained release of active parathyroid hormone (PTH) at stable levels in the physiological range for 24 hours/day.

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced that it has raised $90 million in a Series C financing, bringing its total funding raised to date to $330 million.

Axcella Therapeutics announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright Global Investment Conference taking place September 12 – 14, 2022 both virtually and in-person in New York City.